$ARIA Ariad Pharmaceuticals Inc. Company Overview
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. ARIAD Pharmaceuticals was founded by Harvey J. Berger in April 1991 and is headquartered in Cambridge, MA.
ARIA Last Price: 3.87
Last Updated: November 24, 2013 2:11 AM EST
ARIA Stock Message Board and Forum http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Ariad Pharmaceuticals Inc. ARIA Officers and Executives
Name Age Officer Since Title
Dr. Harvey J. Berger 63 1991 Chairman, President & Chief Executive Officer
Dr. Pierre F. Dodion 58 2007 Senior VP-Corporate Development & Operations
Mr. Edward M. Fitzgerald 58 2002 Chief Financial Officer, Treasurer & Executive VP
Dr. David C. Dalgarno 54 1992 Vice President-Research Technologies
Dr. Timothy P. Clackson 48 1994 Chief Scientific Officer
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139-4234
Phone
1 6174940400
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$558,000
Net Income
$-220.87M
Employees
300.00
Annual Report Below for ARIA
Ariad Pharmaceuticals Inc. ARIA Recent Headlines
MarketWatch News on ARIA
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com
Stocks: Investors play the waiting game 8:53 a.m. Dec. 11, 2012 - The Trading Deck
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Three rules for short selling 12:01 a.m. Feb. 2, 2012 - The Trading Deck
Stocks to watch Wednesday: C.R. Bard, Papa John’s 6:52 a.m. Dec. 21, 2011 - MarketWatch
Don't be a fan when investing 8:26 a.m. Dec. 20, 2011 - The Trading Deck
Drug stocks move higher in late trading 2:26 p.m. March 24, 2011 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:12 p.m. Jan. 18, 2011 - Kate Gibson
Ariad soars as drug indexes move higher 12:47 p.m. Jan. 18, 2011 - Val Brickates Kennedy
Ariad rallies as drug indexes modestly rise 10:23 a.m. Jan. 18, 2011 - Val Brickates Kennedy
Aria rockets on cancer drug data 9:38 a.m. Jan. 18, 2011 - Val Brickates Kennedy
Ariad jumps on leukemia drug data 3:46 p.m. Dec. 6, 2010 - Val Brickates Kennedy
Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales 3:05 p.m. Nov. 22, 2013 - benzinga.com
Mid-Afternoon Market Update: Markets on the Rise as Intel Falls 2:34 p.m. Nov. 22, 2013 - benzinga.com
Time Warner Is the Belle of the Ball: Comcast a Potential Suitor 2:11 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Biotech Stocks Underperforming? These Charts Says Otherwise 12:52 p.m. Nov. 22, 2013 - TheStreet.com
Mid-Day Market Update: US Stocks Gain; Fresh Market Shares Decline On Weak Results 11:57 a.m. Nov. 22, 2013 - benzinga.com
Analysts: EMA Less Severe on Ariad’s Iclusig Than the FDA and 3 More Research Notes to Read 10:29 a.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Mid-Morning Market Update: Markets Open Mixed; Foot Locker Profit Beats Estimates 9:34 a.m. Nov. 22, 2013 - benzinga.com
Ariad Pharmaceuticals (ARIA) Trading With Heavy Volume Before Market Open 8:52 a.m. Nov. 22, 2013 - TheStreet.com
Europe Allows Ariad to Keep Selling Leukemia Drug, Shares Rise 8:46 a.m. Nov. 22, 2013 - TheStreet.com
Ariad gets positive CHMP opinion for continued Iclusig availability 8:45 a.m. Nov. 22, 2013 - Seeking Alpha
Benzinga's Top #PreMarket Gainers 7:21 a.m. Nov. 22, 2013 - benzinga.com
ARIA Stock Spikes 30% in One Day … But Still Down 80% in 2013 4:34 a.m. Nov. 22, 2013 - InvestorPlace.com
2 Pharmas That Should Move After 55th ASH Meeting 10:39 a.m. Nov. 20, 2013 - Seeking Alpha
9 Biotechnology Stocks to Buy Now 6:45 a.m. Nov. 20, 2013 - InvestorPlace.com
Ariad Pharmaceuticals, Inc. Enters Oversold Territory - Tale of the Tape 8:46 a.m. Nov. 18, 2013 - Zacks.com
Benzinga's Top #PreMarket Gainers 7:10 a.m. Nov. 18, 2013 - benzinga.com
7 Biotechnology Stocks to Buy Now 5:00 a.m. Nov. 13, 2013 - InvestorPlace.com
10-Q: ARIAD PHARMACEUTICALS INC 4:36 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Ariad Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript 2:30 p.m. Nov. 12, 2013 - Seeking Alpha
Sirius XM Will Host Baseball Giant Joe Torre and 2 Other Hot Stocks to Watch 12:14 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Press Releases on ARIA
Law Offices of Howard G. Smith Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. -- ARIA 3:32 p.m. Nov. 22, 2013 - GlobeNewswire
ARIA, MU, AMRN and ARUN added to NASDAQ Active Stock Watch List at EPR 10:19 a.m. Nov. 22, 2013 - ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against ARIAD Pharmaceuticals, Inc. and Certain Officers - ARIA 8:00 a.m. Nov. 22, 2013 - PR Newswire
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias 7:46 a.m. Nov. 22, 2013 - BusinessWire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire
Must Watch News & Earnings: Tesla Motors Inc, Pan Global Corp, Ariad Pharmaceuticals, Alpha Natural Resources, Brocade Communications Systems 10:23 a.m. Nov. 19, 2013 - PR Newswire
Appointments, Financial Results, Divestitures, and Staff Reductions- Research Report on AstraZeneca, VIVUS, Cooper, ARIAD, and Amarin 8:00 a.m. Nov. 13, 2013 - PR Newswire
Stock Analysis Reports on AMD, ARIA and GSAT 1:20 a.m. Nov. 13, 2013 - ACCESSWIRE
ARIA, DNDN, HSOL and OREX added to NASDAQ Active Stock Watch List at EPR 9:29 a.m. Nov. 12, 2013 - ACCESSWIRE
Shareholder Rights Law Firm Johnson & Weaver, LLP Files Derivative Lawsuit on behalf of ARIAD Pharmaceuticals, Inc. 9:29 a.m. Nov. 12, 2013 - BusinessWire
ARIAD Reports Third Quarter 2013 Financial Results and Announces Significant Expense Reduction 7:35 a.m. Nov. 12, 2013 - BusinessWire
Glancy Binkow & Goldberg Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. - ARIA 9:10 a.m. Nov. 11, 2013 - GlobeNewswire
News and Updates on ARIA, AFYG and ASAB 1:27 a.m. Nov. 8, 2013 - ACCESSWIRE
ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses 4:05 p.m. Nov. 7, 2013 - BusinessWire
Financial Results and Upcoming Conference Calls - Research Report on Ariad, Idenix, Osiris, InterMune, and Array BioPharma 8:00 a.m. Nov. 6, 2013 - PR Newswire
Harwood Feffer LLP Announces Investigation of Ariad Pharmaceuticals, Inc. 8:10 p.m. Nov. 5, 2013 - PR Newswire
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig 12:50 p.m. Nov. 5, 2013 - PR Newswire
Stock Price Movement Update, Recognitions, and Financial Results - Research Report on Ariad Pharmaceuticals, Quintiles, Molina Healthcare, Exelixis, and Masimo 8:00 a.m. Nov. 4, 2013 - PR Newswire
Today's Equity Reports on BZNE, ARIA, AXPW and SPDL 2:25 a.m. Nov. 4, 2013 - ACCESSWIRE
Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. 9:32 p.m. Nov. 1, 2013 - BusinessWire
Valuation
P/E Current
-2.82
P/E Ratio (with extraordinary items)
-2.69
Price to Sales Ratio
5,670.27
Price to Book Ratio
28.40
Enterprise Value to EBITDA
-1.56
Enterprise Value to Sales
8.25
Total Debt to Enterprise Value
0.00
Efficiency
Revenue/Employee
0.00
Income Per Employee
-0.74
Receivables Turnover
8.27
Total Asset Turnover
0.00
Liquidity
Current Ratio
3.45
Quick Ratio
3.45
Cash Ratio
3.36
Profitability
Operating Margin
-35,888.89
Pretax Margin
-39,582.80
Net Margin
-39,582.80
Return on Assets
-88.19
Return on Equity
-132.66
Return on Total Capital
-123.78
Return on Invested Capital
-125.03
Capital Structure
Total Debt to Total Equity
9.94
Total Debt to Total Capital
9.04
Total Debt to Total Assets
6.22
Long-Term Debt to Equity
8.06
Long-Term Debt to Total Capital
7.33
Ariad Pharmaceuticals Inc. ARIA Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 7.08M 8.3M 178.98M 25.3M 558,000
Cost of Goods Sold (COGS) incl. D&A - - - - -
COGS excluding D&A - - - - -
Depreciation & Amortization Expense 3.02M 4.22M 6.15M 4.61M 3.02M
Depreciation 2.27M 3.19M 5.27M 2.91M 2.8M
Amortization of Intangibles 749,000 1.03M 880,000 1.7M 218,000
Gross Income - - - - -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 75.92M 76.12M 67.93M 97.51M 197.8M
Research & Development 50.84M 63.45M 57.99M 77.74M 139.91M
Other SG&A 25.08M 12.67M 9.95M 19.77M 57.89M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 7.8M 19.53M 46.72M 20.72M
EBIT after Unusual Expense 0 (7.8M) (19.53M) (46.72M) (20.72M)
Non Operating Income/Expense 0 0 0 0 71,000
Non-Operating Interest Income 1.35M 116,000 86,000 167,000 240,000
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 550,000 287,000 206,000 232,000 199,000
Gross Interest Expense 550,000 287,000 206,000 232,000 199,000
Interest Capitalized 0 0 0 0 0
Pretax Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Minority Interest Expense 0 0 0 0 0
Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
EPS (Basic) (1.02) (0.86) 0.75 (0.93) (1.34)
Basic Shares Outstanding 69.79M 93.33M 113.02M 132.38M 164.96M
EPS (Diluted) (1.02) (0.86) 0.74 (0.93) (1.34)
Diluted Shares Outstanding 69.79M 93.33M 114.73M 132.38M 164.96M
EBITDA (68.84M) (67.81M) 111.05M (72.21M) (197.24M)
Ariad Pharmaceuticals Inc. ARIA Filings
SEC Filings for Ariad Pharmaceuticals Inc.
Filing Date Document Date Type Category Amended
11/22/2013 11/22/2013 8-K Special Events
11/12/2013 09/30/2013 10-Q Quarterly Reports
11/12/2013 N/A SC 13G/A Institutional Ownership *
11/12/2013 11/07/2013 8-K Special Events
11/05/2013 10/31/2013 8-K/A Special Events *
11/01/2013 10/31/2013 8-K Special Events
10/31/2013 10/31/2013 8-K Special Events
10/29/2013 N/A SC 13D N/A
10/23/2013 N/A SC 13G Institutional Ownership
10/18/2013 10/18/2013 8-K Special Events
10/09/2013 10/09/2013 8-K Special Events
09/30/2013 09/28/2013 8-K Special Events
09/18/2013 09/16/2013 8-K Special Events
09/04/2013 09/04/2013 8-K Special Events
08/09/2013 06/30/2013 10-Q Quarterly Reports
08/07/2013 08/07/2013 8-K Special Events
07/17/2013 07/15/2013 8-K Special Events
07/02/2013 07/02/2013 8-K Special Events
06/24/2013 06/20/2013 8-K Special Events
06/04/2013 06/01/2013 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
ARIA Ariad Pharmaceuticals Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ARIA/quote
Stock Chart http://www.otcmarkets.com/stock/ARIA/chart
Company Info http://www.otcmarkets.com/stock/ARIA/company-info
Recent News http://www.otcmarkets.com/stock/ARIA/news
Financials http://www.otcmarkets.com/stock/ARIA/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ARIA/filings
Short Sales http://www.otcmarkets.com/stock/ARIA/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ARIA/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ARIA/research
Summary http://finance.yahoo.com/q?s=ARIA
Historical Prices http://finance.yahoo.com/q/hp?s=ARIA+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ARIA
Basic Chart http://finance.yahoo.com/q/bc?s=ARIA+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ARIA+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ARIA+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ARIA+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ARIA+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ARIA+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ARIA+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ARIA+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ARIA+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ARIA+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ARIA
Balance Sheet http://finance.yahoo.com/q/bs?s=ARIA
Cash Flow http://finance.yahoo.com/q/cf?s=ARIA+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ARIA
Market Watch http://www.marketwatch.com/investing/stock/ARIA
Bloomberg http://www.bloomberg.com/quote/ARIA:US
Morningstar http://quotes.morningstar.com/stock/s?t=ARIA
Bussinessweek http://investing.businessweek.com/research/st...icker=ARIA
Barchart http://www.barchart.com/quotes/stocks/ARIA
OTC Short Report http://otcshortreport.com/index.php?index=ARIA
Investopedia http://www.investopedia.com/markets/stocks/ARIA/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. ARIAD Pharmaceuticals was founded by Harvey J. Berger in April 1991 and is headquartered in Cambridge, MA.
ARIA Last Price: 3.87
Last Updated: November 24, 2013 2:11 AM EST
ARIA Stock Message Board and Forum http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Ariad Pharmaceuticals Inc. ARIA Officers and Executives
Name Age Officer Since Title
Dr. Harvey J. Berger 63 1991 Chairman, President & Chief Executive Officer
Dr. Pierre F. Dodion 58 2007 Senior VP-Corporate Development & Operations
Mr. Edward M. Fitzgerald 58 2002 Chief Financial Officer, Treasurer & Executive VP
Dr. David C. Dalgarno 54 1992 Vice President-Research Technologies
Dr. Timothy P. Clackson 48 1994 Chief Scientific Officer
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139-4234
Phone
1 6174940400
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$558,000
Net Income
$-220.87M
Employees
300.00
Annual Report Below for ARIA
Ariad Pharmaceuticals Inc. ARIA Recent Headlines
MarketWatch News on ARIA
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com
Stocks: Investors play the waiting game 8:53 a.m. Dec. 11, 2012 - The Trading Deck
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Three rules for short selling 12:01 a.m. Feb. 2, 2012 - The Trading Deck
Stocks to watch Wednesday: C.R. Bard, Papa John’s 6:52 a.m. Dec. 21, 2011 - MarketWatch
Don't be a fan when investing 8:26 a.m. Dec. 20, 2011 - The Trading Deck
Drug stocks move higher in late trading 2:26 p.m. March 24, 2011 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:12 p.m. Jan. 18, 2011 - Kate Gibson
Ariad soars as drug indexes move higher 12:47 p.m. Jan. 18, 2011 - Val Brickates Kennedy
Ariad rallies as drug indexes modestly rise 10:23 a.m. Jan. 18, 2011 - Val Brickates Kennedy
Aria rockets on cancer drug data 9:38 a.m. Jan. 18, 2011 - Val Brickates Kennedy
Ariad jumps on leukemia drug data 3:46 p.m. Dec. 6, 2010 - Val Brickates Kennedy
Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales 3:05 p.m. Nov. 22, 2013 - benzinga.com
Mid-Afternoon Market Update: Markets on the Rise as Intel Falls 2:34 p.m. Nov. 22, 2013 - benzinga.com
Time Warner Is the Belle of the Ball: Comcast a Potential Suitor 2:11 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Biotech Stocks Underperforming? These Charts Says Otherwise 12:52 p.m. Nov. 22, 2013 - TheStreet.com
Mid-Day Market Update: US Stocks Gain; Fresh Market Shares Decline On Weak Results 11:57 a.m. Nov. 22, 2013 - benzinga.com
Analysts: EMA Less Severe on Ariad’s Iclusig Than the FDA and 3 More Research Notes to Read 10:29 a.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Mid-Morning Market Update: Markets Open Mixed; Foot Locker Profit Beats Estimates 9:34 a.m. Nov. 22, 2013 - benzinga.com
Ariad Pharmaceuticals (ARIA) Trading With Heavy Volume Before Market Open 8:52 a.m. Nov. 22, 2013 - TheStreet.com
Europe Allows Ariad to Keep Selling Leukemia Drug, Shares Rise 8:46 a.m. Nov. 22, 2013 - TheStreet.com
Ariad gets positive CHMP opinion for continued Iclusig availability 8:45 a.m. Nov. 22, 2013 - Seeking Alpha
Benzinga's Top #PreMarket Gainers 7:21 a.m. Nov. 22, 2013 - benzinga.com
ARIA Stock Spikes 30% in One Day … But Still Down 80% in 2013 4:34 a.m. Nov. 22, 2013 - InvestorPlace.com
2 Pharmas That Should Move After 55th ASH Meeting 10:39 a.m. Nov. 20, 2013 - Seeking Alpha
9 Biotechnology Stocks to Buy Now 6:45 a.m. Nov. 20, 2013 - InvestorPlace.com
Ariad Pharmaceuticals, Inc. Enters Oversold Territory - Tale of the Tape 8:46 a.m. Nov. 18, 2013 - Zacks.com
Benzinga's Top #PreMarket Gainers 7:10 a.m. Nov. 18, 2013 - benzinga.com
7 Biotechnology Stocks to Buy Now 5:00 a.m. Nov. 13, 2013 - InvestorPlace.com
10-Q: ARIAD PHARMACEUTICALS INC 4:36 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Ariad Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript 2:30 p.m. Nov. 12, 2013 - Seeking Alpha
Sirius XM Will Host Baseball Giant Joe Torre and 2 Other Hot Stocks to Watch 12:14 p.m. Nov. 12, 2013 - Wall St. Cheat Sheet
Press Releases on ARIA
Law Offices of Howard G. Smith Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. -- ARIA 3:32 p.m. Nov. 22, 2013 - GlobeNewswire
ARIA, MU, AMRN and ARUN added to NASDAQ Active Stock Watch List at EPR 10:19 a.m. Nov. 22, 2013 - ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against ARIAD Pharmaceuticals, Inc. and Certain Officers - ARIA 8:00 a.m. Nov. 22, 2013 - PR Newswire
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias 7:46 a.m. Nov. 22, 2013 - BusinessWire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire
Must Watch News & Earnings: Tesla Motors Inc, Pan Global Corp, Ariad Pharmaceuticals, Alpha Natural Resources, Brocade Communications Systems 10:23 a.m. Nov. 19, 2013 - PR Newswire
Appointments, Financial Results, Divestitures, and Staff Reductions- Research Report on AstraZeneca, VIVUS, Cooper, ARIAD, and Amarin 8:00 a.m. Nov. 13, 2013 - PR Newswire
Stock Analysis Reports on AMD, ARIA and GSAT 1:20 a.m. Nov. 13, 2013 - ACCESSWIRE
ARIA, DNDN, HSOL and OREX added to NASDAQ Active Stock Watch List at EPR 9:29 a.m. Nov. 12, 2013 - ACCESSWIRE
Shareholder Rights Law Firm Johnson & Weaver, LLP Files Derivative Lawsuit on behalf of ARIAD Pharmaceuticals, Inc. 9:29 a.m. Nov. 12, 2013 - BusinessWire
ARIAD Reports Third Quarter 2013 Financial Results and Announces Significant Expense Reduction 7:35 a.m. Nov. 12, 2013 - BusinessWire
Glancy Binkow & Goldberg Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. - ARIA 9:10 a.m. Nov. 11, 2013 - GlobeNewswire
News and Updates on ARIA, AFYG and ASAB 1:27 a.m. Nov. 8, 2013 - ACCESSWIRE
ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses 4:05 p.m. Nov. 7, 2013 - BusinessWire
Financial Results and Upcoming Conference Calls - Research Report on Ariad, Idenix, Osiris, InterMune, and Array BioPharma 8:00 a.m. Nov. 6, 2013 - PR Newswire
Harwood Feffer LLP Announces Investigation of Ariad Pharmaceuticals, Inc. 8:10 p.m. Nov. 5, 2013 - PR Newswire
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig 12:50 p.m. Nov. 5, 2013 - PR Newswire
Stock Price Movement Update, Recognitions, and Financial Results - Research Report on Ariad Pharmaceuticals, Quintiles, Molina Healthcare, Exelixis, and Masimo 8:00 a.m. Nov. 4, 2013 - PR Newswire
Today's Equity Reports on BZNE, ARIA, AXPW and SPDL 2:25 a.m. Nov. 4, 2013 - ACCESSWIRE
Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. 9:32 p.m. Nov. 1, 2013 - BusinessWire
Valuation
P/E Current
-2.82
P/E Ratio (with extraordinary items)
-2.69
Price to Sales Ratio
5,670.27
Price to Book Ratio
28.40
Enterprise Value to EBITDA
-1.56
Enterprise Value to Sales
8.25
Total Debt to Enterprise Value
0.00
Efficiency
Revenue/Employee
0.00
Income Per Employee
-0.74
Receivables Turnover
8.27
Total Asset Turnover
0.00
Liquidity
Current Ratio
3.45
Quick Ratio
3.45
Cash Ratio
3.36
Profitability
Operating Margin
-35,888.89
Pretax Margin
-39,582.80
Net Margin
-39,582.80
Return on Assets
-88.19
Return on Equity
-132.66
Return on Total Capital
-123.78
Return on Invested Capital
-125.03
Capital Structure
Total Debt to Total Equity
9.94
Total Debt to Total Capital
9.04
Total Debt to Total Assets
6.22
Long-Term Debt to Equity
8.06
Long-Term Debt to Total Capital
7.33
Ariad Pharmaceuticals Inc. ARIA Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 7.08M 8.3M 178.98M 25.3M 558,000
Cost of Goods Sold (COGS) incl. D&A - - - - -
COGS excluding D&A - - - - -
Depreciation & Amortization Expense 3.02M 4.22M 6.15M 4.61M 3.02M
Depreciation 2.27M 3.19M 5.27M 2.91M 2.8M
Amortization of Intangibles 749,000 1.03M 880,000 1.7M 218,000
Gross Income - - - - -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 75.92M 76.12M 67.93M 97.51M 197.8M
Research & Development 50.84M 63.45M 57.99M 77.74M 139.91M
Other SG&A 25.08M 12.67M 9.95M 19.77M 57.89M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 7.8M 19.53M 46.72M 20.72M
EBIT after Unusual Expense 0 (7.8M) (19.53M) (46.72M) (20.72M)
Non Operating Income/Expense 0 0 0 0 71,000
Non-Operating Interest Income 1.35M 116,000 86,000 167,000 240,000
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 550,000 287,000 206,000 232,000 199,000
Gross Interest Expense 550,000 287,000 206,000 232,000 199,000
Interest Capitalized 0 0 0 0 0
Pretax Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Minority Interest Expense 0 0 0 0 0
Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
EPS (Basic) (1.02) (0.86) 0.75 (0.93) (1.34)
Basic Shares Outstanding 69.79M 93.33M 113.02M 132.38M 164.96M
EPS (Diluted) (1.02) (0.86) 0.74 (0.93) (1.34)
Diluted Shares Outstanding 69.79M 93.33M 114.73M 132.38M 164.96M
EBITDA (68.84M) (67.81M) 111.05M (72.21M) (197.24M)
Ariad Pharmaceuticals Inc. ARIA Filings
SEC Filings for Ariad Pharmaceuticals Inc.
Filing Date Document Date Type Category Amended
11/22/2013 11/22/2013 8-K Special Events
11/12/2013 09/30/2013 10-Q Quarterly Reports
11/12/2013 N/A SC 13G/A Institutional Ownership *
11/12/2013 11/07/2013 8-K Special Events
11/05/2013 10/31/2013 8-K/A Special Events *
11/01/2013 10/31/2013 8-K Special Events
10/31/2013 10/31/2013 8-K Special Events
10/29/2013 N/A SC 13D N/A
10/23/2013 N/A SC 13G Institutional Ownership
10/18/2013 10/18/2013 8-K Special Events
10/09/2013 10/09/2013 8-K Special Events
09/30/2013 09/28/2013 8-K Special Events
09/18/2013 09/16/2013 8-K Special Events
09/04/2013 09/04/2013 8-K Special Events
08/09/2013 06/30/2013 10-Q Quarterly Reports
08/07/2013 08/07/2013 8-K Special Events
07/17/2013 07/15/2013 8-K Special Events
07/02/2013 07/02/2013 8-K Special Events
06/24/2013 06/20/2013 8-K Special Events
06/04/2013 06/01/2013 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
ARIA Ariad Pharmaceuticals Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ARIA/quote
Stock Chart http://www.otcmarkets.com/stock/ARIA/chart
Company Info http://www.otcmarkets.com/stock/ARIA/company-info
Recent News http://www.otcmarkets.com/stock/ARIA/news
Financials http://www.otcmarkets.com/stock/ARIA/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ARIA/filings
Short Sales http://www.otcmarkets.com/stock/ARIA/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ARIA/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ARIA/research
Summary http://finance.yahoo.com/q?s=ARIA
Historical Prices http://finance.yahoo.com/q/hp?s=ARIA+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ARIA
Basic Chart http://finance.yahoo.com/q/bc?s=ARIA+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ARIA+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ARIA+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ARIA+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ARIA+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ARIA+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ARIA+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ARIA+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ARIA+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ARIA+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ARIA
Balance Sheet http://finance.yahoo.com/q/bs?s=ARIA
Cash Flow http://finance.yahoo.com/q/cf?s=ARIA+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ARIA
Market Watch http://www.marketwatch.com/investing/stock/ARIA
Bloomberg http://www.bloomberg.com/quote/ARIA:US
Morningstar http://quotes.morningstar.com/stock/s?t=ARIA
Bussinessweek http://investing.businessweek.com/research/st...icker=ARIA
Barchart http://www.barchart.com/quotes/stocks/ARIA
OTC Short Report http://otcshortreport.com/index.php?index=ARIA
Investopedia http://www.investopedia.com/markets/stocks/ARIA/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
